Clinical Trial Update: Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating danvatirsen in combination with durvalumab for advanced and refractory colorectal cancer, pancreatic cancer, and non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Danvatirsen (danvatirsen)
• Durvalumab (durvalumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING